研究文章
睡眠呼吸障碍患病率和模式在印度人口心脏衰竭
|
|
HFREF,(%) |
HFPE,(%) |
值(
) |
|
| 性别 |
男性性 |
36 (63.15%) |
27 (58.69%) |
1.00 |
| NYHA |
二世 |
29 (50.87%) |
32 (69.56%) |
0.04 |
| 三世 |
21 (36.84%) |
12 (26.08%) |
| 四世 |
7 (12.28%) |
2 (4.34%) |
| 病因 |
缺血性类型 |
44 (77.19%) |
30 (65.21%) |
0.512 |
| 药物 |
BB |
16 (28.07%) |
14 (30.43%) |
0.664 |
| ACEI / ARB |
10 (17.54%) |
7 (15.21%) |
1.00 |
| 利尿剂 |
44 (77.19%) |
19 (41.30%) |
0.002 |
| MRA |
23 (40.35%) |
1 (2.17%) |
< 0.001 |
| ARNI |
9 (15.78%) |
0 (0%) |
0.009 |
| 并发症 |
2型糖尿病 |
37 (64.91%) |
24 (52.17%) |
0.425 |
| HTN |
24 (42.1%) |
29 (63.04%) |
0.017 |
| 血脂异常 |
17 (29.82%) |
16 (34.78%) |
0.398 |
| 甲状腺功能减退 |
7 (12.28%) |
5 (10.86%) |
1.00 |
| 慢性肾病 |
7 (12.28%) |
2 (4.34%) |
0.294 |
| 房颤 |
4 (7.01%) |
7 (15.21%) |
0.198 |
| 症状 |
打鼾 |
16 (28.07%) |
22 (47.82%) |
0.02 |
| 在睡眠中呜咽 |
15 (26.31%) |
16 (34.78%) |
0.280 |
| 白天嗜睡 |
18 (31.57%) |
17 (36.95%) |
0.408 |
| ESS |
< 10 |
21 (36.84%) |
19 (41.30%) |
0.838 |
| ≥10 |
36 (63.15%) |
27 (58.69%) |
| 停止爆炸风险 |
低风险 |
26 (45.61%) |
7 (15.21%) |
0.006 |
| 中间的风险 |
26 (45.61%) |
31 (67.39%) |
| 高的风险 |
5 (8.77%) |
8 (17.39%) |
| 柏林问 |
高的风险 |
20 (35.08%) |
23 (50%) |
0.072 |
| 低风险 |
37 (64.91%) |
23 (50%) |
|
|
|
HFREF:与射血分数降低心力衰竭;HFpEF:心力衰竭与射血分数保留;NYHA:纽约心脏协会;BB:β受体阻滞剂;ACEI:血管紧张素转换酶抑制剂;ARB:血管紧张素受体阻滞剂;MRA:盐皮质激素受体拮抗剂;neprilysin ARNI:血管紧张素受体抑制剂;2型糖尿病:2型糖尿病;HTN:高血压; CKD: chronic kidney disease; AF: atrial fibrillation; SOB: shortness of breath; ESS: Epworth Sleepiness Scale; Q: questionnaire.
|
